References
- Hansen L, Lyons KS, Dieckmann NF, Chang MF, Hiatt S, Solanki E, Lee CS. Background and design of the symptom burden in end-stage liver disease patient-caregiver dyad study. Res Nurs Health. 2017;40(5):398–413. doi:https://doi.org/10.1002/nur.21807.
- Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. Bmj. 2018;362:k2817. doi:https://doi.org/10.1136/bmj.k2817.
- Asrani SK, Larson JJ, Yawn B, Therneau TM, Kim WR. Underestimation of liver-related mortality in the United States. Gastroenterology. 2013;145(2):375–82.e1-2. doi:https://doi.org/10.1053/j.gastro.2013.04.005.
- Ge PS, Runyon BA, Campion EW. Treatment of patients with cirrhosis. N Engl J Med. 2016;375(8):767–77. doi:https://doi.org/10.1056/NEJMra1504367.
- Habka D, Mann D, Landes R, Soto-Gutierrez A. Future economics of liver transplantation: a 20-year cost modeling forecast and the prospect of bioengineering autologous liver grafts. PLoS One. 2015;10(7):e0131764. doi:https://doi.org/10.1371/journal.pone.0131764.
- Kwong AJ, Kim WR, Lake JR, Smith JM, Schladt DP, Skeans MA, Noreen SM, Foutz J, Booker SE, Cafarella M, et al. OPTN/SRTR 2019 Annual Data Report: liver. Am J Transplant. 2021;21(Suppl 2):208–315. doi:https://doi.org/10.1111/ajt.16494.
- Nishikawa K, Osawa Y, and Kimura K. Wnt/β-Catenin signaling as a potential target for the treatment of liver cirrhosis using antifibrotic drugs. Int J Mol Sci . 2018;10:19.
- Moroni F, Dwyer BJ, Graham C, Pass C, Bailey L, Ritchie L, Mitchell D, Glover A, Laurie A, Doig S, et al. Safety profile of autologous macrophage therapy for liver cirrhosis. Nat Med. 2019;25(10):1560–65. doi:https://doi.org/10.1038/s41591-019-0599-8.
- Schrem H, Klempnauer J, Borlak J. Liver-enriched transcription factors in liver function and development. Part I: the hepatocyte nuclear factor network and liver-specific gene expression. Pharmacol Rev. 2002;54(1):129–58. doi:https://doi.org/10.1124/pr.54.1.129.
- Liu L, Yannam GR, Nishikawa T, Yamamoto T, Basma H, Ito R, Nagaya M, Dutta-Moscato J, Stolz DB, Duan F, et al. The microenvironment in hepatocyte regeneration and function in rats with advanced cirrhosis. Hepatology. 2012;55(5):1529–39. doi:https://doi.org/10.1002/hep.24815.
- Haep N, Florentino RM, Squires JE, Bell A, Soto-Gutierrez A. The Inside-Out of End-Stage Liver Disease: hepatocytes are the Keystone. Semin Liver Dis. 2021;41(2):213–24. doi:https://doi.org/10.1055/s-0041-1725023.
- Guzman-Lepe J, Cervantes-Alvarez E, Collin De L HA, Wang Y, Wm M, Oda Y, Bekki Y, Shimokawa M, Wang H, Yoshizumi T, et al. Liver-enriched transcription factor expression relates to chronic hepatic failure in humans. Hepatol Commun. 2018;2(5):582–94. doi:https://doi.org/10.1002/hep4.1172.
- Babeu JP, Boudreau F, Boudreau F. Hepatocyte nuclear factor 4-alpha involvement in liver and intestinal inflammatory networks. World J Gastroenterol. 2014;20(1):22–30. doi:https://doi.org/10.3748/wjg.v20.i1.22.
- Battle MA, Konopka G, Parviz F, Gaggl AL, Yang C, Sladek FM, Duncan SA. Hepatocyte nuclear factor 4alpha orchestrates expression of cell adhesion proteins during the epithelial transformation of the developing liver. Proc Natl Acad Sci U S A. 2006;103(22):8419–24. doi:https://doi.org/10.1073/pnas.0600246103.
- Parviz F, Matullo C, Garrison WD, Savatski L, Adamson JW, Ning G, Kaestner KH, Rossi JM, Zaret KS, Duncan SA, et al. Hepatocyte nuclear factor 4alpha controls the development of a hepatic epithelium and liver morphogenesis. Nat Genet. 2003;34(3):292–96. doi:https://doi.org/10.1038/ng1175.
- Yeh MM, Bosch DE, Daoud SS. Role of hepatocyte nuclear factor 4-alpha in gastrointestinal and liver diseases. World J Gastroenterol. 2019;25(30):4074–91. doi:https://doi.org/10.3748/wjg.v25.i30.4074.
- Ji D, Chen GF, Wang JC, Cao LH, Lu F, Mu XX, Zhang X-Y, Lu X-J. Identification of TAF1,HNF4A, andCALM2 as potential therapeutic target genes for liver fibrosis. J Cell Physiol. 2019;234(6):9045–51. doi:https://doi.org/10.1002/jcp.27579.
- Nishikawa T, Bell A, Brooks JM, Setoyama K, Melis M, Han B, Fukumitsu K, Handa K, Tian J, Kaestner KH, et al. Resetting the transcription factor network reverses terminal chronic hepatic failure. J Clin Invest. 2015;125(4):1533–44. doi:https://doi.org/10.1172/JCI73137.
- Cox-North P, Doorenbos A, Shannon SE, Scott J, Curtis JR. The transition to end-of-life care in end-stage liver disease. Journal of Hospice & Palliative Nursing. 2013;15(4):209–15. doi:https://doi.org/10.1097/NJH.0b013e318289f4b0.
- Yadav DK, Zhang Q, Bai X, Li E, Liang T. Liver transplantation for alcohol-related liver disease (ARLD): an update on controversies and considerations. Can J Gastroenterol Hepatol. 2020;2020:8862152. doi:https://doi.org/10.1155/2020/8862152.
- D’Souza S, Lau KC, Coffin CS, Patel TR. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma. World J Gastroenterol. 2020;26(38):5759–83. doi:https://doi.org/10.3748/wjg.v26.i38.5759.
- Lin J, Wu JF, Zhang Q, Zhang HW, Cao GW. Virus-related liver cirrhosis: molecular basis and therapeutic options. World J Gastroenterol. 2014;20(21):6457–69. doi:https://doi.org/10.3748/wjg.v20.i21.6457.
- Calzadilla Bertot L, and Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci . 2016;5:17.
- Pierantonelli I. S-BG nonalcoholic fatty Liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH. Transplantation. 2019;103(1):e1–e13. doi:https://doi.org/10.1097/TP.0000000000002480.
- Ma X, Li Z. Pathogenesis of nonalcoholic steatohepatitis (NASH). Chin J Dig Dis. 2006;7(1):7–11. doi:https://doi.org/10.1111/j.1443-9573.2006.00237.x.
- Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis. 2016;20(2):205–14. doi:https://doi.org/10.1016/j.cld.2015.10.001.
- Mazzarelli C, Prentice WM, Heneghan MA, Belli LS, Agarwal K, Cannon MD. Palliative care in end-stage liver disease: time to do better? Liver Transpl. 2018;24(7):961–68. doi:https://doi.org/10.1002/lt.25193.
- Potosek J, Curry M, Buss M, Chittenden E. Integration of palliative care in end-stage liver disease and liver transplantation. J Palliat Med. 2014;17(11):1271–77. doi:https://doi.org/10.1089/jpm.2013.0167.
- Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. Gut. 2015;64(5):830–41. doi:https://doi.org/10.1136/gutjnl-2014-306842.
- Hernaez R, Solà E, Moreau R, Ginès P. Acute-on-chronic liver failure: an update. Gut. 2017;66(3):541–53. doi:https://doi.org/10.1136/gutjnl-2016-312670.
- Nishikawa T, Bellance N, Damm A, Bing H, Zhu Z, Handa K, Yovchev MI, Sehgal V, Moss TJ, Oertel M, et al. A switch in the source of ATP production and a loss in capacity to perform glycolysis are hallmarks of hepatocyte failure in advance liver disease. J Hepatol. 2014;60(6):1203–11. doi:https://doi.org/10.1016/j.jhep.2014.02.014.
- Fang B, Mane-Padros D, Bolotin E, Jiang T, Sladek FM. Identification of a binding motif specific to HNF4 by comparative analysis of multiple nuclear receptors. Nucleic Acids Res. 2012;40(12):5343–56. doi:https://doi.org/10.1093/nar/gks190.
- Azmi AS, Bao GW, Gao J, Mohammad RM, Sarkar FH. Network insights into the genes regulated by hepatocyte nuclear factor 4 in response to drug induced perturbations: a review. Curr Drug Discov Technol. 2013;10(2):147–54. doi:https://doi.org/10.2174/1570163811310020007.
- Gloyn AL, Ellard S, Shepherd M, Howell RT, Parry EM, Jefferson A, Levy ER, Hattersley AT. Maturity-onset diabetes of the young caused by a balanced translocation where the 20q12 break point results in disruption upstream of the coding region of hepatocyte nuclear factor-4alpha (HNF4A) gene. Diabetes. 2002;51(7):2329–33. doi:https://doi.org/10.2337/diabetes.51.7.2329.
- Hadzopoulou-Cladaras M, Kistanova E, Evagelopoulou C, Zeng S, Cladaras C, Ladias JA. Functional domains of the nuclear receptor hepatocyte nuclear factor 4. J Biol Chem. 1997;272(1):539–50. doi:https://doi.org/10.1074/jbc.272.1.539.
- Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell. 1995;83(6):841–50. doi:https://doi.org/10.1016/0092-8674(95)90200-7.
- Lu H. Crosstalk of HNF4α with extracellular and intracellular signaling pathways in the regulation of hepatic metabolism of drugs and lipids. Acta Pharm Sin B. 2016;6(5):393–408. doi:https://doi.org/10.1016/j.apsb.2016.07.003.
- Iyemere VP, Davies NH, Brownlee GG. The activation function 2 domain of hepatic nuclear factor 4 is regulated by a short C-terminal proline-rich repressor domain. Nucleic Acids Res. 1998;26(9):2098–104. doi:https://doi.org/10.1093/nar/26.9.2098.
- Suaud L, Formstecher P, Laine B. The activity of the activation function 2 of the human hepatocyte nuclear factor 4 (HNF-4alpha) is differently modulated by F domains from various origins. Biochem J. 1999;340(1):161–69. doi:https://doi.org/10.1042/bj3400161.
- Qu M, Duffy T, Hirota T, Kay SA. Nuclear receptor HNF4A transrepresses CLOCK:BMAL1 and modulates tissue-specific circadian networks. Proc Natl Acad Sci U S A. 2018;115(52):E12305–e12. doi:https://doi.org/10.1073/pnas.1816411115.
- Taniguchi H, Fujimoto A, Kono H, Furuta M, Fujita M, Nakagawa H. Loss-of-function mutations in Zn-finger DNA-binding domain of HNF4A cause aberrant transcriptional regulation in liver cancer. Oncotarget. 2018;9(40):26144–56. doi:https://doi.org/10.18632/oncotarget.25456.
- Drewes T, Senkel S, Holewa B, Ryffel GU. Human hepatocyte nuclear factor 4 isoforms are encoded by distinct and differentially expressed genes. Mol Cell Biol. 1996;16:925–31. doi:https://doi.org/10.1128/MCB.16.3.925.
- Gonzalez FJ. Regulation of hepatocyte nuclear factor 4 alpha-mediated transcription. Drug Metab Pharmacokinet. 2008;23(1):2–7. doi:https://doi.org/10.2133/dmpk.23.2.
- Sladek FM, Zhong WM, Lai E, Darnell JE Jr. Liver-enriched transcription factor HNF-4 is a novel member of the steroid hormone receptor superfamily. Genes Dev. 1990;4(12b):2353–65. doi:https://doi.org/10.1101/gad.4.12b.2353.
- Carrière V, Vidal R, Lazou K, Lacasa M, Delers F, Ribeiro A, Rousset M, Chambaz J, Lacorte JM. HNF-4-dependent induction of apolipoprotein A-IV gene transcription by an apical supply of lipid micelles in intestinal cells. J Biol Chem. 2005;280(7):5406–13. doi:https://doi.org/10.1074/jbc.M408002200.
- Hwang-Verslues WW, Sladek FM. HNF4α—role in drug metabolism and potential drug target? Curr Opin Pharmacol. 2010;10(6):698–705. doi:https://doi.org/10.1016/j.coph.2010.08.010.
- Bolotin E, Liao H, Ta TC, Yang C, Hwang-Verslues W, Evans JR, Jiang T, Sladek FM. Integrated approach for the identification of human hepatocyte nuclear factor 4alpha target genes using protein binding microarrays. Hepatology. 2010;51(2):642–53. doi:https://doi.org/10.1002/hep.23357.
- Lau HH, Ng NHJ, Loo LSW, Jasmen JB, Teo AKK. The molecular functions of hepatocyte nuclear factors - In and beyond the liver. J Hepatol. 2018;68(5):1033–48. doi:https://doi.org/10.1016/j.jhep.2017.11.026.
- Huang J, Levitsky LL, Rhoads DB. Novel P2 promoter-derived HNF4α isoforms with different N-terminus generated by alternate exon insertion. Exp Cell Res. 2009;315(7):1200–11. doi:https://doi.org/10.1016/j.yexcr.2009.01.004.
- Wang J-C, Stafford JM, Dk G. SRC-1 and GRIP1 coactivate transcription with hepatocyte nuclear factor 4*. Journal of Biological Chemistry. 1998;273(47):30847–50. doi:https://doi.org/10.1074/jbc.273.47.30847.
- Barrero MJ, Malik S. Two functional modes of a nuclear receptor-recruited arginine methyltransferase in transcriptional activation. Mol Cell. 2006;24(2):233–43. doi:https://doi.org/10.1016/j.molcel.2006.09.020.
- Soutoglou E, Katrakili N, Talianidis I. Acetylation regulates transcription factor activity at multiple levels. Mol Cell. 2000;5(4):745–51. doi:https://doi.org/10.1016/S1097-2765(00)80253-1.
- Yokoyama A, Katsura S, Ito R, Hashiba W, Sekine H, Fujiki R, Kato S. Multiple post-translational modifications in hepatocyte nuclear factor 4α. Biochem Biophys Res Commun. 2011;410(4):749–53. doi:https://doi.org/10.1016/j.bbrc.2011.06.033.
- Hong YH, Varanasi US, Yang W, Leff T. AMP-activated protein kinase regulates HNF4alpha transcriptional activity by inhibiting dimer formation and decreasing protein stability. J Biol Chem. 2003;278(30):27495–501. doi:https://doi.org/10.1074/jbc.M304112200.
- Ko HL, Zhuo Z, Ren EC. HNF4α combinatorial isoform heterodimers activate distinct gene targets that differ from their corresponding homodimers. Cell Rep. 2019;26(10):2549–2557.e3. doi:https://doi.org/10.1016/j.celrep.2019.02.033.
- É L, Babeu J-P, Simoneau J, Raisch J, Lavergne L, Lévesque D, Jolibois É, Avino M, Scott MS, Boudreau F, et al. Human hepatocyte nuclear factor 4-α encodes isoforms with distinct transcriptional functions. Mol Cell Proteomics. 2020;19(5):808–27. doi:https://doi.org/10.1074/mcp.RA119.001909.
- Briançon N, Weiss MC. In vivo role of the HNF4alpha AF-1 activation domain revealed by exon swapping. EMBO J. 2006;25(6):1253–62. doi:https://doi.org/10.1038/sj.emboj.7601021.
- Guo S, Lu H. Novel mechanisms of regulation of the expression and transcriptional activity of hepatocyte nuclear factor 4α. J Cell Biochem. 2019;120(1):519–32. doi:https://doi.org/10.1002/jcb.27407.
- Walesky C, Gunewardena S, Terwilliger EF, Edwards G, Borude P, Apte U. Hepatocyte-specific deletion of hepatocyte nuclear factor-4α in adult mice results in increased hepatocyte proliferation. Am J Physiol Gastrointest Liver Physiol. 2013;304:G26–G37. doi:https://doi.org/10.1152/ajpgi.00064.2012.
- Walesky C, Apte U. Role of hepatocyte nuclear factor 4α (HNF4α) in cell proliferation and cancer. Gene Expr. 2015;16(3):101–08. doi:https://doi.org/10.3727/105221615X14181438356292.
- Wu H, Reizel T, Wang YJ, Lapiro JL, Kren BT, Schug J, Rao S, Morgan A, Herman A, Shekels LL, et al. A negative reciprocal regulatory axis between cyclin D1 and HNF4α modulates cell cycle progression and metabolism in the liver. Proc Natl Acad Sci U S A. 2020;117(29):17177–86. doi:https://doi.org/10.1073/pnas.2002898117.
- Huck I, Gunewardena S, Espanol-Suner R, Willenbring H, Apte U. Hepatocyte nuclear factor 4 alpha activation is essential for termination of liver regeneration in mice. Hepatology (Baltimore, Md). 2019;70(2):666–81. doi:https://doi.org/10.1002/hep.30405.
- Dubois V, Staels B, Lefebvre P, Verzi MP, Eeckhoute J. Control of cell identity by the nuclear receptor HNF4 in organ pathophysiology. Cells. 2020;9(10):2185. doi:https://doi.org/10.3390/cells9102185.
- Florentino RM, Fraunhoffer NA, Morita K, Takeishi K, Ostrowska A, Achreja A, Animasahun O, Haep N, Arazov S, Agarwal N, et al. Cellular location of HNF4α is linked with terminal liver failure in humans. Hepatology Communications. 2020;4(6):859–75. doi:https://doi.org/10.1002/hep4.1505.
- Morales-Ruiz M, Santel A, Ribera J, Jiménez W. The role of Akt in chronic liver disease and liver regeneration. Semin Liver Dis. 2017;37:11–16. doi:https://doi.org/10.1055/s-0036-1597819.
- Yu D, Chen G, Pan M, Zhang J, He W, Liu Y, Nian, X, Sheng , L, and Xu, B, High fat diet-induced oxidative stress blocks hepatocyte nuclear factor 4α and leads to hepatic steatosis in mice. J Cell Physiol. 2018;233(6):4770–82. doi:https://doi.org/10.1002/jcp.26270.
- Marcil V, Sinnett D, Seidman E, Boudreau F, Gendron FP, Beaulieu JF, Menard D, Lambert M, Bitton A, Sanchez R, et al. Association between genetic variants in the HNF4A gene and childhood-onset Crohn’s disease. Genes Immun. 2012;13(7):556–65. doi:https://doi.org/10.1038/gene.2012.37.
- Chahar S, Gandhi V, Yu S, Desai K, Cowper-sal-lari R, Kim Y, Perekatt AO, Kumar N, Thackray JK, Musolf A, et al. Chromatin profiling reveals regulatory network shifts and a protective role for hepatocyte nuclear factor 4α during colitis. Mol Cell Biol. 2014;34(17):3291–304. doi:https://doi.org/10.1128/MCB.00349-14.
- Lausen J, Thomas H, Lemm I, Bulman M, Borgschulze M, Lingott A, Hattersley, A T, and Riffel, G U, Naturally occurring mutations in the human HNF4alpha gene impair the function of the transcription factor to a varying degree. Nucleic Acids Res. 2000;28(2):430–37. doi:https://doi.org/10.1093/nar/28.2.430.
- Jrm E, Formstecher P, Maturity-Onset LB. Diabetes of the young type 1 (MODY1)-Associated mutations R154X and E276Q in hepatocyte nuclear factor 4α (HNF4α) gene impair recruitment of p300, a key transcriptional coactivator. Molecular Endocrinology. 2001;15:1200–10.
- Oxombre B, Moerman E, Eeckhoute J, Formstecher P, Laine B. Mutations in hepatocyte nuclear factor 4α (HNF4α) gene associated with diabetes result in greater loss of HNF4α function in pancreatic β-cells than in nonpancreatic β-cells and in reduced activation of the apolipoprotein CIII promoter in hepatic cells. J Mol Med. 2002;80(7):423–30. doi:https://doi.org/10.1007/s00109-002-0340-8.
- Sebastiani G, Gkouvatsos K, Pantopoulos K. Chronic hepatitis C and liver fibrosis. World J Gastroenterol. 2014;20(32):11033–53. doi:https://doi.org/10.3748/wjg.v20.i32.11033.
- Pinzani M, Rombouts K, Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol. 2005;42(Suppl):S22–36. doi:https://doi.org/10.1016/j.jhep.2004.12.008.
- Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371(9615):838–51. doi:https://doi.org/10.1016/S0140-6736(08)60383-9.
- Chang Y, Li H. Hepatic antifibrotic pharmacotherapy: are we approaching success? J Clin Transl Hepatol. 2020;8(2):222–29. doi:https://doi.org/10.14218/JCTH.2020.00026.
- Rockey DC. Antifibrotic therapy in chronic liver disease. Clin Gastroenterol Hepatol. 2005;3(2):95–107. doi:https://doi.org/10.1016/S1542-3565(04)00445-8.
- Lazarevich NL, Cheremnova OA, Varga EV, Ovchinnikov DA, Kudrjavtseva EI, Morozova OV, Fleishman DI, Engelhardt NV, Duncan SA. Progression of HCC in mice is associated with a downregulation in the expression of hepatocyte nuclear factors. Hepatology. 2004;39(4):1038–47. doi:https://doi.org/10.1002/hep.20155.
- Yue HY, Yin C, Hou JL, Zeng X, Chen YX, Zhong W, Hu, PF, Deng, X, Tan, YX, and Zhang, JP, Hepatocyte nuclear factor 4alpha attenuates hepatic fibrosis in rats. Gut. 2010;59:236–46
- Verbeke R, Lentacker I, Wayteck L, Breckpot K, Van Bockstal M, Descamps B, Vanhove C, De Smedt SC, Dewitte H. Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: restoring the immunogenicity of immunosilent mRNA. J Control Release. 2017;266:287–300. doi:https://doi.org/10.1016/j.jconrel.2017.09.041.
- Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, Julander JG, Tang WW, Shresta S, Pierson TC, et al. Modified mRNA vaccines protect against Zika Virus Infection. Cell. 2017;168(6):1114–25.e10. doi:https://doi.org/10.1016/j.cell.2017.02.017.
- Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, Himansu S, Schäfer A, Ziwawo CT, DiPiazza AT, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586(7830):567–71. doi:https://doi.org/10.1038/s41586-020-2622-0.
- Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020;383(25):2427–38. doi:https://doi.org/10.1056/NEJMoa2028436.